07.13.10
Continuing a strategic cooperation, Cognis has licensed two new active ingredients for weight management and cognitive performance from InterMed Discovery (IMD), further expanding the company’s innovation pipeline.
During their ongoing collaboration, Cognis and IMD have utilized IMD’s database of biologically active natural substances and its unique IMD Bioprofiling technology platform to discover innovative functional ingredients for specific food applications, and to bring suitable active substances to market-readiness.
One of the candidates is a new ingredient that is showing promising benefits for weight management in different test systems. The second new ingredient is a product for improving brain health, as in vivo tests have shown potential on cognitive performance. Cognis plans to carry out further in vivo tests and research studies for these ingredients later this year.
Cognis has already licensed four other ingredients from IMD targeting weight management and heart health. Clinical studies for one of these projects will begin later this year. The other licensed ingredients are currently in advanced preclinical testing and scale-up process.
During their ongoing collaboration, Cognis and IMD have utilized IMD’s database of biologically active natural substances and its unique IMD Bioprofiling technology platform to discover innovative functional ingredients for specific food applications, and to bring suitable active substances to market-readiness.
One of the candidates is a new ingredient that is showing promising benefits for weight management in different test systems. The second new ingredient is a product for improving brain health, as in vivo tests have shown potential on cognitive performance. Cognis plans to carry out further in vivo tests and research studies for these ingredients later this year.
Cognis has already licensed four other ingredients from IMD targeting weight management and heart health. Clinical studies for one of these projects will begin later this year. The other licensed ingredients are currently in advanced preclinical testing and scale-up process.